Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia coli

키워드

참고문헌 (24)

1. Arora A, "Role of tyrosine kinase inhibitors in cancer therapy", J. Pharmacol. Exp. Ther, 315, pp.971~979 (2005)
2. Baneyx F., "Recombinant protein expression in Escherichia coli", Curr. Opin. Biotechnol, 10, pp.411~421 (1999)
3. Brignola PS, "Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors", J. Biol. Chem, 277, pp.1576~1585 (2002)
4. Carvalho JÉF, "Vascular endothelial growth factor (VEGF) in autoimmune diseases", J. Clin. Immunol, 27, pp.246~256 (2007)
5. Doughervermazen M, "Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor", Biochem. Biophys. Res. Commun, 205, pp.728~738 (1994)
6. Dyson MR, "Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression", BMC. Biotechnol, 4, pp.32~ (2004)
7. Ferrara N., "Role of vascular endothelial growth factor in regulation of physiological angiogenesis", Am. J. Physiol. Cell Physiol, 280, pp.C1358~C1366 (2001)
8. Ferrara N, "The biology of VEGF and its receptors", Nat. Med, 9, pp.669~676 (2003)
9. Guo XN, "Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B", Biochem. Biophys. Acta, 1673, pp.186~193 (2004)
10. Hammarström M, "Rapid screening for improved solubility of small human proteins produced as fusion proteins in Escherichia coli", Protein Sci, 11, pp.313~321 (2002)
11. Liu C, "Expression and purification of human vascular endothelial growth factor receptor 2 tyrosine kinase in Streptomyces for inhibitor screening", Biotechnol. Appl. Biochem, 50, pp.113~119 (2008)
12. O’Farrell AM, "SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo", Blood, 101, pp.3597~3605 (2003)
13. Parast CV, "Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis", Biochemistry, 37, pp.16788~16801 (1998)
14. Rabhi-Essafi I, "A strategy for high-level expression of soluble and functional human interferon α as a GST-fusion protein in E. coli", Protein Eng. Des. Sel, 20, pp.201~209 (2007)
15. Sakurai Y, "Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice", Proc. Natl. Acad. Sci. USA, 102, pp.1076~1081 (2005)
16. Sambrook JR, "Molecular Cloning: A Laboratory Manual" (2001), Cold Spring Harbor Laboratory Press
17. Tugues S, "Vascular endothelial growth factors and receptors:anti-angiogenic therapy in the treatment of cancer", Mol. Aspects. Med, 32, pp.88~111 (2011)
18. Veeravagu A, "Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as antiangiogenic agents in cancer therapy", Recent. Pat. Anticancer Drug Discov, 2, pp.59~71 (2007)
19. Wang Y, "Targeting expression of the catalytic domain of the kinase insert domain receptor (KDR) in the peroxisomes of Pichia pastoris", FEMS Yeast Res, 9, pp.732~741 (2009)
20. Widmann M, "Comparison of folding rates of homologous prokaryotic and eukaryotic proteins", J. Biol. Chem, 275, pp.18619~18622 (2000)
21. Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF", MEK, Cancer Res, pp.2004, 64[DOI]
22. Wood JM, "PTK787", ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factorinduced responses and tumor growth after oral administration, 2000, pp.60, 2178~2189
23. Zhao G, "Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase", Anal. Biochem, 360, pp.196~206 (2007)
24. Zhong L, "Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening", Biochem. Biophys. Acta, 1722, pp.254~261 (2005)

관련 논문AI추천